Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Suma Krishnan, a Director and President, R&D at Krystal Biotech , Inc. (NASDAQ:KRYS), sold a total of $5.39 million in company stock between July 14 and July 16, 2025. The sales, executed under a pre-arranged 10b5-1 trading plan, involved multiple transactions with prices ranging from $150.00 to $151.79 per share.
On July 14, Krishnan sold 13,335 shares at a weighted average price of $150.2906, in a range of $150.00 to $150.97, and 100 shares at $151.00. On July 15, she sold 2,236 shares at a weighted average price of $150.6839, in a range of $150.21 to $151.18, and 800 shares at $151.79. On July 16, Krishnan sold 1,529 shares at $150.00. These transactions decreased Krishnan’s direct holdings to 1,438,711 shares. The company’s strong liquidity position is reflected in its robust current ratio of 9.65.
In addition, Krishnan’s spouse also sold shares. On July 14, 13,400 shares were sold at a weighted average price of $150.2996, in a range of $150.00 to $150.98. On July 15, 2,184 shares were sold at a weighted average price of $150.6817, in a range of $150.21 to $151.00, and 900 shares were sold at $151.79. On July 16, 1,389 shares were sold at $150.00. Following these transactions, the spouse’s holdings decreased to 1,508,056 shares. These sales were also executed under a pre-arranged 10b5-1 trading plan.
Krishnan also has indirect ownership of Krystal Biotech stock through the SMK Trust (90,000 shares) and the Krishnan Family Trust (50,000 shares).
In other recent news, Krystal Biotech has dosed the first patient in its Phase 1/2 EMERALD-1 trial, which is evaluating the investigational eye drop gene therapy KB801 for neurotrophic keratitis (NK), a rare eye disease. This trial is a randomized, double-masked, multicenter, placebo-controlled study that will enroll up to 27 adults. The primary aim is to assess the safety and tolerability of KB801, with secondary objectives focusing on efficacy measures. Citi has responded to this development by raising its price target for Krystal Biotech to $176, citing KB801 as an "underappreciated asset" with potential advantages over existing treatments. Clear Street has also initiated coverage of Krystal Biotech with a Buy rating and a $190 price target, noting the potential for upside from ongoing pipeline programs. H.C. Wainwright has maintained its Buy rating and $240 price target ahead of Krystal Biotech’s anticipated Q2 2025 financial results. The firm remains optimistic about the launch trajectory of Vyjuvek, Krystal’s commercial product for dystrophic epidermolysis bullosa. These recent developments underscore the market’s focus on Krystal Biotech’s clinical progress and financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.